Pneumagen

Pneumagen is a startup based in the United Kingdom. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 3 investors associated with the company.

Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral intranasal drug for the prophylaxis and treatment of viral respiratory tract infections. The therapy targets viral pathogens by binding to epithelial cell surface receptors in the respiratory tract to prevent infection.